SCHEMBL280148

SCHEMBL280148

Cc1ccc(C(=O)CNc2ccncn2)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.43
ADORA2B P29275 2/20 0.43
KMT2A Q03164 2/20 0.41
POLB P06746 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
RAB9A P51151 5/20 0.40
NPC1 O15118 3/20 0.40
DAO P14920 1/20 0.39
MEN1 O00255 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 3/20 0.37
NAMPT P43490 1/20 0.37
HPGD P15428 2/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL280368 0.82 KMT2A (0.44) ADORA2AADORA2BKMT2APOLBTDP1
SCHEMBL280361 0.80 RAB9A (0.47) KMT2APOLBTDP1RAB9ANPC1
SCHEMBL279749 0.77 KMT2A (0.42) ADORA2AADORA2BKMT2APOLBTDP1
SCHEMBL280375 0.75 GSK3B (0.47) POLBRAB9ANPC1ALDH1A1NAMPT
SCHEMBL279739 0.73 ALDH1A1 (0.47) ADORA2AADORA2BKMT2APOLBTDP1
SCHEMBL2401814 0.73 P2RX7 (0.44) KMT2ARAB9AHTTSMN1; SMN2CYP1A2
SCHEMBL280197 0.72 RAB9A (0.48) KMT2APOLBTDP1RAB9ANPC1
SCHEMBL4419704 0.72 SMN1; SMN2 (0.48) KMT2APOLBMEN1ALDH1A1HTT
SCHEMBL279924 0.72 NAMPT (0.40) NAMPTHTTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL4466178 0.71 P2RX7 (0.47) HTTSMN1; SMN2CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL ADORA2A 726/4885ADORA2B 454/4885KMT2A 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.